Journal Home
Search for

Volume 21, Issue 1, Pages 82-85 (January 2010)


View previous. 13 of 14 View next.

Dissolution of a harm reduction track for opiate agonist treatment: Longitudinal impact on treatment retention, substance use and service utilization

Bryan HartzlerCorresponding Author Informationemail address, Ann J. Cotton, Donald A. Calsyn, Rachael Guerra, Edward Gignoux

Received 27 October 2008; received in revised form 22 January 2009; accepted 27 January 2009. published online 12 March 2009.

Abstract 

Background

There is great need to sustain harm reduction programmes for opiate-dependent persons, given variable retention of opioid agonist treatment (OAT) enrolees. Resource challenges may lead some health organizations to discontinue such programmes, though just as programmatic evaluation may determine efficacy and cost-effectiveness so to does it aid in examining impacts of programme dissolution.

Methods

This retrospective evaluation investigated impacts of the dissolution of a ‘Minimal Services’ (MS) harm reduction programme for substance-abusing OAT clientele at an urban U.S. Veterans Affairs Medical Centre. Targeted clinical data concerning treatment retention, substance use and service utilization was abstracted from medical records of MS-assignees (N=32) and a matched comparison group of standard OAT enrolees. Chart reviewers gathered data for a two-year period encompassing baseline, transitional, and dissolution study phases.

Results

Relative to matched-controls, MS-assignees exhibited: (1) disproportionately poor treatment retention over the two-year period; (2) high and temporally stable rates of documented substance use across study phases, and (3) increased utilization of resource-laden VAMC services after MS dissolution.

Conclusion

Collective results suggest MS programme dissolution was associated with adverse conditions for assignees and the larger treatment setting, and reinforce the need for pragmatic, humane treatment policies to facilitate retention of opiate-dependent persons.

Alcohol & Drug Abuse Institute, University of Washington, Box 354805, 1107 NE 45th Street, Suite 120, Seattle, WA 98105-4631, USA

Corresponding Author InformationCorresponding author. Tel.: +1 206 543 8369; fax: +1 206 543 5473.

PII: S0955-3959(09)00043-7

doi:10.1016/j.drugpo.2009.01.005


View previous. 13 of 14 View next.